May 18, 2022
Dr. Mark Berman is the Chief Medical Officer at Better Therapeutics, using a prescription digital therapeutic to treat diseases caused by human behavior, particularly type II diabetes. While PDT model might be expected to be effective with younger patients, clinical trial data is revealing that older patients 60+ are...
May 18, 2022
Dr. Mark Berman is the Chief Medical Officer at Better Therapeutics, using a prescription digital therapeutic to treat diseases caused by human behavior, particularly type II diabetes. While PDT model might be expected to be effective with younger patients, clinical trial data is revealing that older patients 60+ are...
May 17, 2022
Dr. Tom Lendvay is the Chief Medical Officer of Tend, which addresses the gut microbiome of the severe intestinal infection Clostridium difficile CDIF. Currently, recurrent Clostridium difficile is the only FDA-regulated disease for the use of microbiome transplants outside of a clinical trial. Clinical trials are also...
May 17, 2022
Dr. Tom Lendvay is the Chief Medical Officer of Tend, which addresses the gut microbiome of the severe intestinal infection Clostridium difficile CDIF. Currently, recurrent Clostridium difficile is the only FDA-regulated disease for the use of microbiome transplants outside of a clinical trial. Clinical trials are also...
May 16, 2022
Russ Thomas, the CEO of Availity, and Oron Afek, CEO and Co-Founder of Vim, join me in discussing the benefits of breaking down information silos of the payers and care providers and bringing real-time data to the point of care. By integrating actionable patient information at the right point of time, providers are...